| DIRECT COMPETITOR COMPARISON | |
| GPRO | ABT | RHHBY.PK | Pvt1 | Industry | | Market Cap: | 2.06B | 83.65B | N/A | N/A | 75.08M | | Employees: | 991 | 69,000 | N/A | N/A | 217 | | Qtrly Rev Growth (yoy): | 1.30% | 3.50% | N/A | N/A | 11.90% | | Revenue (ttm): | 468.57M | 29.92B | N/A | N/A | 56.04M | | Gross Margin (ttm): | 70.09% | 58.31% | N/A | N/A | 35.56% | | EBITDA (ttm): | 157.39M | 8.64B | N/A | N/A | -2.13M | | Oper Margins (ttm): | 26.02% | 22.32% | N/A | N/A | -5.87% | | Net Income (ttm): | 88.90M | 5.60B | N/A | N/A | N/A | | EPS (ttm): | 1.706 | 3.691 | N/A | N/A | N/A | | P/E (ttm): | 24.61 | 14.65 | N/A | N/A | 19.44 | | PEG (5 yr expected): | 1.55 | 1.27 | 1.45 | N/A | 1.47 | | P/S (ttm): | 4.43 | 2.81 | N/A | N/A | 1.80 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ABT | | Digital Angiography Pump Monitor Creates Investment Opportunity In Utah Based Small Cap Medical Device Company
Sat 10:28am -
Wall Street Transcript | | • | ABT | | A Mostly Meaningless FDA Approval
Fri 11:18am -
at Motley Fool | | • | ABT | | INSIDE WASHINGTON: Stream of WH health care visits
Thu, Nov 26 -
AP | | • | ABT | | AP IMPACT: A stream of WH health care visits
Wed, Nov 25 -
AP | | • | ABT | | A Big Upgrade for Amylin Pharmaceuticals
Wed, Nov 25 -
at Motley Fool | | • | RHHBY.PK | | Inhibition of Cell Migration by Gene Silencing - Measured with the xCELLigence Cell Analysis System from Roche
Wed, Nov 25 -
Business Wire | | • | RHHBY.PK | | Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Mon, Nov 23 -
PR Newswire | | • | RHHBY.PK | | Spectrum Pharma: Zevalin Sales Ramp Up
Sun, Nov 22 -
at Seeking Alpha | | • | RHHBY.PK | | Desktop Bug Detector
Fri, Nov 20 -
at Forbes.com | | • | RHHBY.PK | | Biotech Stocks: Senate bill weighs on Allergan, Medicis
Thu, Nov 19 -
at MarketWatch | | • | RHHBY.PK | | 454 Life Sciences Unveils New Bench Top Sequencer, Significant Improvements to the Genome Sequencer FLX System Including 1,000 bp Reads for 2010
Thu, Nov 19 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
